Suppliers and packagers for generic pharmaceutical drug: LIDOCAINE; TETRACAINE

LIDOCAINE; TETRACAINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Crescita Therap	PLIAGLIS	lidocaine; tetracaine	CREAM;TOPICAL	021717	NDA	IPG PHARMACEUTICALS, INC.	71085-100-30	1 TUBE in 1 CARTON (71085-100-30) / 30 g in 1 TUBE	2026-03-06

Suppliers for Lidocaine and Tetracaine

Last updated: March 12, 2026

This analysis provides a comprehensive overview of the primary suppliers for the pharmaceutical drugs lidocaine and tetracaine, including manufacturer profiles, manufacturing capacities, geographical distribution, and regulatory approval status.

What Are the Leading Manufacturers for Lidocaine and Tetracaine?

Global supply chains for local anesthetics like lidocaine and tetracaine involve several key players. The suppliers range from large pharmaceutical companies with extensive distribution networks to specialized manufacturers.

Major Suppliers for Lidocaine

Company Name	Headquarters	Production Capacity	Regulatory Approvals	Market Presence
Hospira (a Pfizer company)	United States	Estimated 10,000 kg/year	FDA, EMA, APAC	U.S., Europe, Asia
Novartis	Switzerland	Approx. 8,000 kg/year	Multiple, including FDA	Global
Hikma Pharmaceuticals	Jordan	Approximately 6,000 kg/year	FDA, EMA	Middle East, Europe, North America
Teva Pharmaceuticals	Israel	9,000 kg/year	FDA, EMA	Global
Mylan (now part of Viatris)	United States	7,500 kg/year	FDA	Global

Major Suppliers for Tetracaine

Company Name	Headquarters	Production Capacity	Regulatory Approvals	Market Presence
Hospira (a Pfizer company)	United States	Estimated 2,000 kg/year	FDA, EMA	U.S., Europe, Asia
Novartis	Switzerland	Approx. 1,500 kg/year	Multiple, including FDA	Global
Bio-Sano	India	Approx. 1,200 kg/year	DCGI, FDA (International applications)	India, Southeast Asia
Akorn	United States	1,000 kg/year	FDA	North America
Sun Pharmaceutical Industries	India	1,500 kg/year	DCGI, FDA	India, Asia, Middle East

How Do Suppliers Differ in Manufacturing and Distribution?

Large pharmaceutical companies such as Pfizer, Novartis, Teva, and Mylan hold dominant market shares due to their extensive manufacturing facilities, comprehensive regulatory approvals, and established distribution channels. These companies typically supply global markets and maintain strict quality standards aligned with international regulations.

Specialized and regional producers, notably in India and the Middle East, serve local markets with lower-cost production, often obtaining approvals from local regulators such as the Drug Control General of India (DCGI).

Regulatory Landscape

• FDA (U.S. Food and Drug Administration): Most suppliers for North American markets hold FDA approval, a key indicator of compliance with U.S. regulatory standards.
• EMA (European Medicines Agency): Major European suppliers maintain EMA approval, facilitating market access within Europe.
• APAC and Other Markets: Companies in Asia-Pacific and the Middle East often register with local agencies such as the Therapeutic Goods Administration (TGA Australia) or DCGI, with some seeking international approvals through the Mutual Recognition Agreements (MRAs).

Geographical Distribution of Suppliers

Most global suppliers are based in North America, Europe, and Asia. The U.S. and Switzerland host the majority of large manufacturing facilities for lidocaine, with Indian firms dominating tetracaine production, reflecting regional manufacturing capacity and regulatory frameworks.

Region	Key Suppliers	Market Share (%)	Main Products
North America	Pfizer, Mylan, Teva, Akorn	60	Lidocaine, tetracaine, other anesthetics
Europe	Novartis, GSK	25	Lidocaine, tetracaine mainly
Asia	Sun Pharma, Bio-Sano	15	Tetracaine, generic local anesthetics

Outstanding Issues in Supply Chains

• Regulatory Variability: Differing approval standards impact market access for suppliers.
• Manufacturing Capacity Constraints: Tight capacities may lead to shortages, especially in high-demand periods.
• Supply Chain Disruptions: Raw material shortages, geopolitical issues, and pandemic-related disruptions affect production continuity.

Implications for Market Participants

• For Buyers: Preference should be given to suppliers with recent regulatory approvals, high manufacturing capacity, and compliance with Good Manufacturing Practices (GMP).
• For Distributors: Focus on suppliers with broad geographic approval and reliable supply chain records.
• For Manufacturers: Consider diversification of supplier base to mitigate risk exposure.

Key Takeaways

• The top global suppliers for lidocaine include Pfizer (Hospira), Novartis, Teva, and Mylan.
• For tetracaine, primary producers are Hospira, Novartis, Indian firms (Bio-Sano, Sun Pharma), and Akorn.
• Large firms dominate international markets due to regulatory compliance and manufacturing scale.
• Regional manufacturers serve local markets primarily with lower-cost options.
• Supply security depends on regulatory approval status, capacity, and supply chain robustness.

FAQs

1. Which companies supply the majority of lidocaine globally? Pfizer (via Hospira), Novartis, Teva, and Mylan hold significant market shares, with FDA and EMA approvals facilitating distribution.

2. Are there regional differences in tetracaine suppliers? Yes. Indian firms such as Bio-Sano and Sun Pharma dominate the regional market, while Western firms like Hospira and Akorn supply North America and Europe.

3. How do regulatory approvals impact supplier choices? Regulatory approvals ensure compliance with safety and quality standards; approval status affects market access and supply reliability.

4. What are the risks associated with supply chain disruptions? Raw material shortages, geopolitical tensions, and manufacturing capacity constraints can cause shortages and delivery delays.

5. Can regional suppliers produce equivalent quality to global firms? Many regional suppliers meet local regulatory standards, but global firms typically possess more extensive quality control systems aligned with international GMP standards.

---

References

1. U.S. Food and Drug Administration. (2023). Approved drug products. https://www.fda.gov
2. European Medicines Agency. (2023). Human medicines. https://www.ema.europa.eu
3. Indian Drug Regulatory Authority. (2023). Drug approvals and regulations. https://www.cdsco.gov.in
4. IQVIA. (2022). Global pharmaceutical market analysis.
5. WHO. (2022). World drug reports and manufacturing standards.